Brief: Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
12/05/2026 13:56
May 12 (Reuters) - VistaGen Therapeutics Inc VTGN.O: VISTAGEN ANNOUNCES PRELIMINARY POSITIVE DATA IN ONGOING OPEN-LABEL EXTENSION PORTION OF PALISADE-3 PHASE 3 STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER VISTAGEN THERAPEUTICS INC - FASEDIENOL NASAL SPRAY WELL-TOLERATED WITH NO NEW SAFETY FINDINGS AFTER 12 MONTHS VISTAGEN THERAPEUTICS INC - PALISADE-4 TOPLINE DATA EXPECTED IN Q2 2026 VISTAGEN THERAPEUTICS INC - NO SERIOUS ADVERSE EVENTS RELATED TO FASEDIENOL REPORTED Source text: ID:nBw3RY1Xqa Further company coverage: VTGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors